RegenxBio. has been granted a patent for a method to treat mucopolysaccharidosis II (MPS II) by delivering recombinant human iduronate-2-sulfatase (IDS) to the central nervous system. The method includes diagnosing MPS II through D2S6 levels in biological samples and calculating specific ratios of disaccharides. GlobalData’s report on RegenxBio gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on RegenxBio, Adeno-associated virus vectors was a key innovation area identified from patents. RegenxBio's grant share as of June 2024 was 7%. Grant share is based on the ratio of number of grants to total number of patents.